we also feel that EXEL is the superior value option right now. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys.

The sales of syringes and needles in the Gulf Cooperation Council (GCC) region are expected to witness steady growth, with a projected compound annual growth rate (CAGR) of 5.40% through 2034. Market ...

The Zacks Consensus Estimate has increased $0.04 to $1.97 per share. EXEL boasts an average earnings surprise of 26.5%. With a solid Zacks Rank and top-tier Value and VGM Style Scores, EXEL should ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Exelixis (EXEL) reports results for ... to be $561.76 million, up 17.1% from the year-ago quarter.

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

Adding to its momentum, EXEL recently partnered with pharmaceutical heavyweight Merck & Co., Inc. (MRK) to explore zanzalintinib’s potential combined with MRK’s blockbuster PD-1 therapy Keytruda ...

Locals near a needle exchange site in a Bronx park are cheering a councilman’s proposal to require city health workers to collect hundreds of discarded syringes littering the ground. Oswald ...

In its prior filing, the firm reported owning 15,163K shares , representing an increase of 1.28%. The firm increased its portfolio allocation in EXEL by 3.72% over the last quarter. IJH - iShares ...

On Monday, Exelixis (NASDAQ:EXEL) shares, with a market capitalization ... contributing to full-year product sales around $1.805 billion, marking an 11% year-over-year growth.